Lv2
172 积分 2024-09-27 加入
Site-specific antibody labeling via endo-S2 mediated Fc glycan remodeling
1个月前
已关闭
The Challenge of CMC Regulatory Compliance for Biopharmaceuticals
2个月前
已完结
Process Development of Site-Specific Antibody–Drug Conjugates
2个月前
已完结
Antibody–Drug Conjugates Drug Product Formulation and Process Development, Scalability and Stability Considerations
2个月前
已完结
From R&D to Clinical Supplies
2个月前
已完结
Antibody–Drug Conjugates: An Overview of theCMCand Characterization Process
2个月前
已完结
CMC Regulatory Considerations for Antibody-Drug Conjugates
2个月前
已完结
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial
2个月前
已完结
From linker stability to linker fitness: redefining ADC design for clinical translation
3个月前
已关闭
Linker Design for the Antibody Drug Conjugates: A Comprehensive Review
3个月前
已完结
皖公网安备34019202002308
